EBV latency II-derived peptides induce a specific CD4 + cytotoxic T-cell activity and not a CD4 + regulatory T-cell response

Journal of Immunotherapy

Volumn 35, Issue 3, 2012, Pages 254-266

  Moralès, Olivier ^a   Depil, Stéphane ^a,b   Mrizak, Dhafer ^a   Martin, Nathalie ^a   Ndour, Papa Alioune ^a   Dufosse, Françoise ^c   Miroux, Céline ^a   Coll, Jean ^a   De Launoit, Yvan ^a   Auriault, Claude ^d   Pancre, Véronique ^a   Delhem, Nadira ^a  

^a UNIV LILLE   (France)

^b Centre de Biologie Pathologie   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

BV; CD4 + CTL; class II epitopes; regulatory T cells

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; LATENT MEMBRANE PROTEIN 2;

ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LYMPHOBLASTOID CELL; MEMORY T LYMPHOCYTE; NASOPHARYNX CARCINOMA; NK T CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; VIRUS LATENCY;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; HUMANS; IMMUNOLOGIC MEMORY; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; VIRAL MATRIX PROTEINS;

EID: 84858758382     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31824d72c5     Document Type: Article

References (60)

1. Niedobitek G, Young LS. Epstein-Barr virus persistence and virus-associated tumours. Lancet. 1994;343:333-335.
2. Gregory CD, Dive C, Henderson S, et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature. 1991;349:612-614. (Pubitemid 21912115)
3. Bochkarev A, Barwell JA, Pfuetzner RA, et al. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell. 1996;84:791-800. (Pubitemid 26094208)
4. Kaye KM, Izumi KM, Mosialos G, et al. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol. 1995;69:675-683.
5. Wang D, Liebowitz D, Wang F, et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol. 1988;62:4173-4184.
6. Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science. 1999;286:300-303. (Pubitemid 29484694)
7. Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995;80:389-399.
8. Gires O, Kohlhuber F, Kilger E, et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 1999;18:3064-3073. (Pubitemid 29255615)
9. Kieser A, Kaiser C, Hammerschmidt W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J. 1999;18:2511-2521. (Pubitemid 29213283)
10. Kieser A, Kilger E, Gires O, et al. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 1997;16:6478-6485. (Pubitemid 27483273)
11. Fukuda M, Longnecker R. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J Virol. 2007;81:9299-9306. (Pubitemid 47311472)
12. Pang MF, Lin KW, Peh SC. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer. Cell Mol Biol Lett. 2009;14:222-247.
13. Shi Y, Smith KD, Kurilla MG, et al. Cytotoxic CD8+ T cells recognize EBV antigen but poorly kill autologous EBVinfected B lymphoblasts: immunodominance is elicited by a peptide epitope that is presented at low levels in vitro. J Immunol. 1997;159:1844-1852. (Pubitemid 127484172)
14. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474-478.
15. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
16. Cardin RD, Brooks JW, Sarawar SR, et al. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med. 1996;184:863-871.
17. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med. 1998;188:2199-2204. (Pubitemid 29028492)
18. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205-2213. (Pubitemid 29028493)
19. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431. (Pubitemid 27169287)
20. Omiya R, Buteau C, Kobayashi H, et al. Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol. 2002; 169:2172-2179. (Pubitemid 34857685)
21. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 2005;23: 413-419. (Pubitemid 41324359)
22. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001;22:269-276.
23. Dace DS, Chen PW, Alizadeh H, et al. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner. J Leukoc Biol. 2007;81:421-429. (Pubitemid 46198393)
24. Jellison ER, Kim SK, Welsh RM. Cutting edge: MHC class IIrestricted killing in vivo during viral infection. J Immunol. 2005;174:614-618. (Pubitemid 40094252)
25. May RJ, Dao T, Pinilla-Ibarz J, et al. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007;13(15 part 1): 4547-4555. (Pubitemid 47219725)
26. Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001;75:8649-8659. (Pubitemid 32768969)
27. Long HM, Haigh TA, Gudgeon NH, et al. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol. 2005;79:4896-4907. (Pubitemid 40464240)
28. Munz C, Bickham KL, Subklewe M, et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med. 2000;191:1649-1660. (Pubitemid 30331564)
29. Steigerwald-Mullen P, Kurilla MG, Braciale TJ. Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1. J Virol. 2000;74:6748-6759. (Pubitemid 30470657)
30. Demachi-Okamura A, Ito Y, Akatsuka Y, et al. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci. 2008;99:1633-1642.
31. Khanna R, Burrows SR, Thomson SA, et al. Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J Immunol. 1997;158:3619-3625. (Pubitemid 127488714)
32. Paludan C, Bickham K, Nikiforow S, et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol. 2002;169:1593-1603. (Pubitemid 34809208)
33. Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol. 2008;173:195-204. (Pubitemid 351947967)
34. Lamprecht B, Kreher S, Anagnostopoulos I, et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood. 2008;112:3339-3347.
35. Lau KM, Cheng SH, Lo KW, et al. Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients. Brit J Cancer. 2007;96:617-622.
36. Marshall NA, Culligan DJ, Tighe J, et al. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol. 2007;35:596-604. (Pubitemid 46427965)
37. Pai S, O'Sullivan B, Abdul-Jabbar I, et al. Nasopharyngeal carcinoma-associated Epstein-Barr virus-encoded oncogene latent membrane protein 1 potentiates regulatory T-cell function. Immunol Cell Biol. 2007;85:370-377. (Pubitemid 47035607)
38. Takegawa S, Jin Z, Nakayama T, et al. Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder. Cancer Sci. 2008;99:296-302. (Pubitemid 351228483)
39. Depil S, Morales O, Castelli FA, et al. Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. J Immunother. 2007;30:215-226. (Pubitemid 46667801)
40. Groux H, Cottrez F, Montpellier C, et al. Isolation and characterization of transformed human T-cell lines infected by Epstein-Barr virus. Blood. 1997;89:4521-4530. (Pubitemid 27260262)
41. Masy E, Adriaenssens E, Montpellier C, et al. Human monocytic cell lines transformed in vitro by Epstein-Barr virus display a type II latency and LMP-1-dependent proliferation. J Virol. 2002;76:6460-6472. (Pubitemid 34633511)
42. Voo KS, Peng G, Guo Z, et al. Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res. 2005;65:1577-1586. (Pubitemid 40270188)
43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. (Pubitemid 34164012)
44. Ding YH, Smith KJ, Garboczi DN, et al. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity. 1998;8:403-411. (Pubitemid 28196795)
45. Kataoka T, Shinohara N, Takayama H, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin-and Fas-based lytic pathways in cellmediated cytotoxicity. J Immunol. 1996;156:3678-3686. (Pubitemid 26139940)
46. Hartigan-O'Connor DJ, Poon C, Sinclair E, et al. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods. 2007;319:41-52. (Pubitemid 46110995)
47. Hislop AD, Taylor GS, Sauce D, et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617. (Pubitemid 46697918)
48. Han S, Huang Y, Liang Y, et al. Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications. J Hematol Oncol. 2009;2:34-49.
49. Bickham K, Munz C, Tsang ML, et al. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest. 2001;107:121-130. (Pubitemid 32047421)
50. Sun Q, Burton RL, Lucas KG. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood. 2002;99:3302-3309. (Pubitemid 34525311)
51. Wilson AD, Redchenko I, Williams NA, et al. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Int Immunol. 1998;10:1149-1157. (Pubitemid 28362689)
52. Adhikary D, Behrends U, Boerschmann H, et al. Immunodominance of lytic cycle antigens in epstein-barr virusspecific CD4+ T cell preparations for therapy. PLoS One. 2007;2:e583.
53. Wilson AD, Hopkins JC, Morgan AJ. In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein-Barr virus (EBV) seropositive donors. Clin Exp Immunol. 2001;126:101-110. (Pubitemid 32989498)
54. Ochoa MT, Stenger S, Sieling PA, et al. T-cell release of granulysin contributes to host defense in leprosy. Nat Med. 2001;7:174-179. (Pubitemid 32148483)
55. Zhang Y, Chaux P, Stroobant V, et al. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol. 2003;171:219-225. (Pubitemid 36745291)
56. Barath S, Aleksza M, Keresztes K, et al. Immunoregulatory T cells in the peripheral blood of patients with Hodgkin's lymphoma. Acta Haematol. 2006;116:181-185. (Pubitemid 44532962)
57. Frisan T, Sjoberg J, Dolcetti R, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood. 1995;86:1493-1501.
58. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103: 1755-1762. (Pubitemid 38268969)
59. Gandhi MK, Lambley E, Duraiswamy J, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006;108:2280-2289. (Pubitemid 44497511)
60. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol. 2003;170:6183-6189. (Pubitemid 36682602)